Aposense Ltd. Secures $10.25 Million Funding Round; Announces Merger with SirVir and name change to “Interna Therapeutics”
November 4, 2024
Petach Tikvah, Israel – November 4th, 2024
Aposense Ltd., a leader in macromolecule transmembrane delivery, today announced that it has secured $10.25 million in a funding round supported by the Bill & Melinda Gates Foundation. This significant investment will accelerate the company’s pioneering efforts in developing novel prophylactic and therapeutic solutions for infectious diseases, with an initial focus on SARS-CoV-2. As well as the continued development of the company’s groundbreaking macromolecule drug delivery platform.
Concurrently, Aposense Ltd. is merging with its subsidiary, SirVir, and rebranding the newly combined entity as “Interna Therapeutics”. This rebranding reflects the company’s expanded mission to deliver next-generation therapeutic platforms and underscores its commitment to addressing some of the world’s most pressing healthcare challenges.
The funds raised will also support the commencement of a Phase I clinical trial to test the safety and tolerability of a groundbreaking SARS-CoV-2 prophylactic nasal spray. Recruitment for the trial has already begun, marking a critical step forward in the global fight against COVID-19, and future pandemic threats.
Professor Roger Kornberg, Scientific President of Interna Therapeutics and Nobel Laureate in Chemistry, emphasized the scientific innovation driving the company: “The integration of SirVir’s cutting-edge capabilities into Interna Therapeutics allows us to push the boundaries of molecular design and therapeutic development. We are now better positioned to deliver novel solutions to the global healthcare community.”
Yuval Gottenstein, CEO of Interna Therapeutics, expressed his enthusiasm for the funding and the strategic developments: “This significant investment by the Bill & Melinda Gates Foundation greatly enhances our ability to further develop the core technology. The merger with SirVir, under the new Interna Therapeutics brand, represents a transformative step for our company, enabling us to accelerate our efforts to address some of the world’s most pressing healthcare challenges.”
About Interna Therapeutics
Interna Therapeutics is a is a highly innovative Israeli bio-pharmaceutical company, specializing in the development of a universal platform entitled Molecular Nano-Motors (MNMs) for the delivery of macromolecule drugs into cells, utilizing membrane electrical forces. The company is at the forefront of the fight against infectious respiratory diseases.